Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.
- DOI
- 10.1038/s41698-026-01630-8
- Published
- 2026 Jul 30
- Container
- NPJ precision oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41698-026-01630-8,
title = {Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.},
author = {Cederlund A and Struyf N and Rico Pizarro L and Östling P and Sonnevi K and Wahlin BE and Erkers T},
year = {2026},
journal = {NPJ precision oncology},
doi = {10.1038/s41698-026-01630-8},
url = {https://doi.org/10.1038/s41698-026-01630-8}
}RIS
TY - JOUR TI - Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies. AU - Cederlund A AU - Struyf N AU - Rico Pizarro L AU - Östling P AU - Sonnevi K AU - Wahlin BE AU - Erkers T PY - 2026 JO - NPJ precision oncology DO - 10.1038/s41698-026-01630-8 UR - https://doi.org/10.1038/s41698-026-01630-8 ER -
APA
A, C., N, S., L, R. P., P, Ö., K, S., BE, W., & T, E. (2026). Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.. NPJ precision oncology. https://doi.org/10.1038/s41698-026-01630-8